NCT02018419View on ClinicalTrials.gov

Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Metastatic Breast Cancer
Interventions
BIOLOGICAL

AlloStim

AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.

PROCEDURE

Cryoablation

Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.

Trial Locations (1)

92123

Medical Oncology Associates of San Diego, San Diego

Sponsors
All Listed Sponsors
lead

Mirror Biologics, Inc.

INDUSTRY

NCT02018419 - Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter